28 jun: Når lav risiko giver højt afkast
17 jul: Test
12-07-2012 09:37:00

Actelion Launches First Job Cuts

Relateret indhold
Relateret debat
30 aug - 
Godt nyt for menneskeheden.....og for Novartis' aktionæ..

By John Revill

ZURICH--Actelion Ltd. (ATLN.VX) will cut its workforce by up to 5% as part of its new cost-cutting program, as Europe's biggest biotechnology company by sales wrestles with the strong Swiss franc and the tough European market.

The cuts will be the first at Actelion since it was founded in 1997.

The company, based in Allschwil, Switzerland, Thursday said it could reduce up to 135 positions from its 2,500-strong workforce by the end of 2012, but didn't say how much it hopes to save from the cuts.

"In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.

Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, Actelion said.

Pharmaceutical companies have recently been forced to act on steep drug price cuts in Europe and the U.S. and declining revenues as patents on key drugs expire.

Last month, Swiss pharmaceutical company Roche Holding AG (ROG.VX) said it would close a research-and-development site in Nutley, N.J., while Novartis AG (NVS) said in January it needs to save between $1.5 billion and $2.5 billion this year to stay on track.

Actelion, founded by two former Roche scientists, has been dealt a string of product setbacks, and is now banking on a new lung and heart drug called macitentan to become its new blockbuster product.

The company announced that it would be embarking on a cost-saving program in May. At the time, it said earnings wouldn't grow again until 2014 as new medicines and cost cuts would take time to offset falling sales of key pulmonary hypertension drug Tracleer.

Actelion has previously forecast flat core earnings for 2012 as it prepares for declines in sales of Tracleer, which accounts for around 90% of company sales but goes off patent in 2015.

In the first three months of 2012, the company reported a 16% decline in core earnings in Swiss francs--almost double the 9% fall in local currencies--as the currency traded at high levels against the dollar and the euro.

Actelion also Thursday said it is refocusing its R&D efforts toward rare diseases and specialty indications to generate more specialty franchises.

At 0704 GMT, Actelion shares were down CHF0.31, or 0.8%, at CHF40.56.

Write to John Revill at john.revill@dowjones.com

(END) Dow Jones Newswires

July 12, 2012 03:37 ET (07:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Novo: Analysehus ser høj encifret markedsvækst i USA - citat

23-10-2017 12:09:27
Det amerikanske marked for diabetesbehandling vil årligt vokse med høje encifrede vækstrater i det kommende årti, vurderer analysehuset Decision Resources ifølge Bloomberg Intelligence.Fremgangen vil være drevet af nye produkter, bredere funderede tilskud og stigende forekomst af diabetes, vurderer analysehuset.Markedet for apparatur til måling af blodsukkeret ventes at klare sig bedst og vil iføl..

Aktier/middag: Banker trækker ned i C20 løftet af FLS og DSV

23-10-2017 11:27:28
Med FLSmidth og DSV som trækheste ligger det danske C20 Cap-indeks mandag ved 11.15-tiden 0,3 pct. højere i 1186,20 og følger en lettere positiv tendens på hovedparten af de øvrige børser i Europa.Markedet kunne fra morgenstunden hente støtte i stigninger i Japan, hvor investorerne reagerede positivt på, at premierminister Shinzo Abe genvandt flertallet i parlamentet.Usikkerhed er der imidlertid f..

Aktier/tendens: Dobbeltløft til Novo inden blød start på aktieugen

23-10-2017 08:27:22
Aktiemarkedet lægger an til en morgen uden de store bølgeskvulp mandag. Weekenden har budt på få nyheder uden store konsekvenser for de finansielle markeder, og mandagens kalender giver en blød start på ugen, hvor der dog tirsdag, onsdag og torsdag bliver mere travlt med regnskaber og rentemøde i Den Europæiske Centralbank.I morgentimerne mandag indikerer de europæiske aktiefutures, at de store in..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Dobbeltløft til Novo inden blød start på aktieugen
2
Novo: Analysehus ser høj encifret markedsvækst i USA - citat
3
Novo/SHB: Kursmål sættes op til 403 kr. fra 357 kr. - NY
4
Aktier/Sydbank: Der skal opjusteringer til for at forlænge aktiefesten
5
Storbanks mistænkte valutasvindel fanget på bånd

Relaterede aktiekurser

Novartis N 85,10 0,8% Stigning i aktiekurs
Roche GS 235,10 0,3% Stigning i aktiekurs
Roche I 237,80 0,4% Stigning i aktiekurs
Actelion N 274,75 0,4% Stigning i aktiekurs
Novartis AG 85,74 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. oktober 2017 15:28:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171020.1 - EUROWEB7 - 2017-10-23 15:28:12 - 2017-10-23 15:28:12 - 1 - Website: OKAY